Effects of cardiomyopeptidin on myocardial injury in ICU patients: a prospective randomized controlled pilot study
This prospective randomized controlled pilot study suggests that cardiomyopeptidin (CMP) may significantly reduce the incidence of major adverse cardiac events and lower specific cardiac biomarkers in critically ill patients with myocardial injury, warranting further investigation into its therapeutic potential.